{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:12:21Z","timestamp":1764828741700,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00304","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T10:07:05Z","timestamp":1584698825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses"],"prefix":"10.3389","volume":"11","author":[{"given":"Nicoletta","family":"Schintu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Stroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander A.","family":"Math\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per E.","family":"Andr\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease\u2013epidemiology, mechanisms and management.","volume":"8","author":"Aarsland","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease.","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1212\/wnl.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/wnr.0b013e3281668bf7","article-title":"Isolated flinders sensitive line rats have decreased dopamine D2 receptor mRNA.","volume":"18","author":"Bj\u00f8rnebekk","year":"2007","journal-title":"Neuroreport"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson\u2019s disease.","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.biopsych.2012.09.031","article-title":"Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.","volume":"73","author":"Drevets","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/mp.2010.131","article-title":"Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT\/MEK\/Arc signaling in restoration.","volume":"17","author":"Eriksson","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial.","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA- induced dyskinesia in Parkinson\u2019s disease.","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease.","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"B13","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease.","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.brainresbull.2012.01.010","article-title":"Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.","volume":"87","author":"Kova\u010devi\u0107","year":"2012","journal-title":"Brain Res. Bull."},{"key":"B15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mds.10387","article-title":"Higher incidence of depression preceding the onset of Parkinson\u2019s disease: a register study.","volume":"18","author":"Leentjens","year":"2003","journal-title":"Mov. Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease.","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0166-2236(89)90096-9","article-title":"Stimulus-transcription coupling in neurons: role of cellular immediate- early genes.","volume":"12","author":"Morgan","year":"1989","journal-title":"Trends Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"16827","DOI":"10.1074\/jbc.275.22.16827","article-title":"Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors.","volume":"275","author":"Nevrivy","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1600-0447.2001.00372.x","article-title":"Increased risk of developing Parkinson\u2019s disease for patients with major affective disorder: a register study.","volume":"104","author":"Nilsson","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"B20","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson\u2019s disease.","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neubiorev.2005.03.015","article-title":"The Flinders Sensitive Line rat: a selectively bred putative animal model of depression.","volume":"29","author":"Overstreet","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1124\/pr.111.005397","article-title":"The flinders sensitive line rat model of depression\u201325 years and still producing.","volume":"65","author":"Overstreet","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.128.2.141","article-title":"Depression in patients with Parkinsonism.","volume":"128","author":"Robins","year":"1976","journal-title":"Br. J. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s0301-0082(98)00053-7","article-title":"Tremulous jaw movements in rats: a model of parkinsonian tremor.","volume":"56","author":"Salamone","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease.","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00524","article-title":"Opioidergic modulation of striatal circuits, implications in Parkinson\u2019s disease and levodopa induced Dyskinesia.","volume":"9","author":"Sgroi","year":"2018","journal-title":"Front. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2013.11.034","article-title":"Antidepressant effects on serotonin 1A\/1B receptors in the rat brain using a gene x environment model.","volume":"559","author":"Shrestha","year":"2014","journal-title":"Neurosci. Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/bioinformatics\/btq410","article-title":"ANAIS: analysis of NimbleGen arrays interface.","volume":"26","author":"Simon","year":"2010","journal-title":"Bioinformatics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/sj.emboj.7601651","article-title":"Crystal structures of autoinhibitory PDZ domain of Tamalin: implications for metabotropic glutamate receptor trafficking regulation.","volume":"26","author":"Sugi","year":"2007","journal-title":"EMBO J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study.","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neures.2005.03.004","article-title":"A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson\u2019s disease.","volume":"52","author":"Tomiyama","year":"2005","journal-title":"Neurosci. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/mds.27465","article-title":"Frequency of mood and anxiety fluctuations in Parkinson\u2019s disease patients with motor fluctuations: a systematic review.","volume":"33","author":"van der Velden","year":"2018","journal-title":"Mov. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neuroscience.2006.12.001","article-title":"Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.","volume":"145","author":"Wang","year":"2007","journal-title":"Neuroscience"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/cne.22605","article-title":"Distribution, level, pharmacology, regulation, and signaling of 5-HT6 receptors in rats and marmosets with special reference to an experimental model of parkinsonism.","volume":"519","author":"Zhang","year":"","journal-title":"J. Comp. Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00213-011-2356-7","article-title":"Antidepressant-like properties of sarizotan in experimental Parkinsonism.","volume":"218","author":"Zhang","year":"","journal-title":"Psychopharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.brainres.2006.04.019","article-title":"Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson\u2019s disease.","volume":"1095","author":"Zhang","year":"2006","journal-title":"Brain Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T10:07:09Z","timestamp":1584698829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":37,"alternative-id":["10.3389\/fphar.2020.00304"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00304","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"article-number":"304"}}